𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A phase II study of gemcitabine and capecitabine in metastatic renal cancer : A report of Cancer and Leukemia Group B protocol 90008

✍ Scribed by Walter M. Stadler; Susan Halabi; Brian Rini; Marc S. Ernstoff; Enrique Davila; Joel Picus; Robert Barrier; Eric J. Small; for Cancer; Leukemia Group B

Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
100 KB
Volume
107
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase II trial of etoposide and cisplati
Phase II trial of etoposide and cisplatin for refractory small cell lung cancer: A cancer and leukemia group B study
✍ Graziano, Stephen L. ;Lee, Kewchang ;Propert, Kathleen J. ;Tinsley, Roger ;Hayes πŸ“‚ Article πŸ“… 1990 πŸ› John Wiley and Sons 🌐 English βš– 466 KB πŸ‘ 1 views

## Abstract A phase II trial of etoposide and cisplatin for patients with previously treated small cell lung cancer was carried out by CALGB from June 1983 to May 1984. Thirty‐five evaluable patients who had failed one prior chemotherapy regimen were treated with etoposide 80 mg/m^2^ and cisplatin

Phase II study of high-dose fish oil cap
Phase II study of high-dose fish oil capsules for patients with cancer-related cachexia : A Cancer and Leukemia Group B study
✍ C. Patrick Burns; Susan Halabi; Gerald Clamon; Ellen Kaplan; Raymond J. Hohl; Ja πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 133 KB πŸ‘ 3 views

## Abstract ## BACKGROUND The authors undertook a multiinstitutional Phase II cooperative group study to examine the potential of oral fish oil fatty acid supplements administered at high doses to slow weight loss and to improve quality of life in patients with malignancy‐related cachexia. ## MET

Phase I/II study of bisantrene in childh
Phase I/II study of bisantrene in childhood cancer: A report from the childrens cancer study group
✍ Movassaghi, Nasser ;Krivit, William A. ;Krailo, Mark D. ;Hammond, G. Denman πŸ“‚ Article πŸ“… 1988 πŸ› John Wiley and Sons 🌐 English βš– 328 KB

A phase I/II study of bisantrene using a 3-week schedule was undertaken in 171 children with refractory leukemias and solid tumors. The doses ranged from 190 to 430 mg/m2. The maximum tolerated dose for children with solid tumors and acute leukemias was 280 mg/m2 and 360 mg/m2 every 3 weeks, respect